<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="233245">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038935</url>
  </required_header>
  <id_info>
    <org_study_id>3082B1-305</org_study_id>
    <nct_id>NCT00038935</nct_id>
  </id_info>
  <brief_title>Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A</brief_title>
  <official_title>A Single Dose, Randomized, Double-Blind, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of B-Domain Deleted Recombinant Human Factor VIII (BDDrFVIII) Manufactured by the Current Process (ReFacto) and by an Albumin Free Manufacturing Process (ReFacto AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relative bioavailability of ReFacto AF as
      compared to ReFacto, when each is administered as 2-minute bolus infusions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">February 2003</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <condition>Hemophilia A</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ReFacto AF</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hemophilia A (FVIII:C &lt; 1% at local laboratory)

          -  Previously treated patients (PTP) with at least 250 exposure days to any factor VIII
             product

          -  Age greater than or equal to 12 years\

        Exclusion Criteria:

          -  The presence of any bleeding disorder in addition to hemophilia A

          -  Concomitant therapy with immunosuppressant drugs (e.g., intravenous immunoglobulin
             (IVIG), routine systemic corticosteroid use)

          -  History of detectable factor VIII inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2008</verification_date>
  <lastchanged_date>April 18, 2008</lastchanged_date>
  <firstreceived_date>June 5, 2002</firstreceived_date>
  <keyword>Hemophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
